In this week’s episode of #AskDrDurie, IMF Chairman Dr. Brian G.M. Durie looks at the factors of myeloma that affect the choice of treatment, including the type of myeloma and any chromosome abnormalities, as well as genetic testing done on the patient.

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
Bringing Next Generation Flow (NGF) Cytometry to Japan
Next Post
Is it possible to boost the immune system for myeloma patients?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.